Association Between Diabetic Retinopathy, Dietary Inflammatory Index and Metabolic Syndrome in Azar Cohort Study

Mohammad Hossein Somi
liver and Gastrointestinal Diseases Research center, Tabriz University of Medical Sciences

Zeinab Nikniaz
Liver and Gastrointestinal Diseases Research center

Mohammad Asghari Jafarabadi
Medical Education Research Center, Department of S

Amir Taher Eftekarsadat
Pathology Department of Imam Reza Hospital, Tabriz,

Mohammad Mirzaei
Department of Ophthalmology Tabriz University of Medical Sciences

Uffe Holmskov
Department of Cancer and Inflammation Research.

Jakob Grauslund
Odense University Hospital, Odense, Denmark. 2) Research unit of Ophthalmology, Department of Clinical Research, University of Southern Denmark, 3) Steno Diabetes Center Odense, Odense, Denmark

Nitin Shivappa
University of South Carolina, Columbia, SC 29208

James R. Hébert
University of South Carolina, Columbia, SC 29208

Elnaz Faramarzi (elnazfaramarzi849@gmail.com)
liver and Gastrointestinal Diseases Research center, Tabriz University of Medical Sciences  
https://orcid.org/0000-0003-4128-433X

Ali Reza Ostadrahimi
Nutrition Research Center: Tabriz University of Medical Sciences

Research article

Keywords: Type 2 diabetes, diabetic retinopathy, non-proliferative diabetic retinopathy, proliferative diabetic retinopathy, metabolic syndrome

DOI: https://doi.org/10.21203/rs.3.rs-107350/v1

License: © ① This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

Background: The aim of present study was to evaluate the association between diabetic retinopathy (DR), dietary inflammatory index (DII), and metabolic syndrome (MetS) in patients with type 2 diabetes in a cohort study in Iran.

Methods: This cross-sectional study was a part of the large Azar eye cohort study that included 1378 patients with type 2 diabetes. To diagnose DR, two mydriatic fundus photographs were captured using a digital fundus camera. The DR severity was classified as non-proliferative diabetic retinopathy (NPDR) or proliferative diabetic retinopathy (PDR). MetS was determined on the basis of the ATPIII criteria. DII was calculated according to Shivappa et al. method.

Results: Of 1378 diabetic patients, 185 (13.4%) had NPDR and 142 (10.3%) had PDR. The risk of NPDR and PDR increased by 2.65-fold and 2.01-fold, respectively, in patients having blood glucose levels that fell outside the recommended range. There was no statistically significant relationship between Mets, Mets components, and DII in NPDR and PDR.

Conclusion: The results suggest that intensive glycemic control, rather than conventional control, may help reduce the progression of DR. It seems that longitudinal studies and clinical trials for evaluating role of DII in DR are necessary.

1. Background

Diabetic retinopathy (DR) is the most common microvascular complication of diabetes and is a leading cause of blindness in developing countries [1]. Due to the increasing prevalence of diabetes, it is expected that the prevalence of DR also will increase. DR is commonly observed in almost all type 1 diabetic patients and in more than 60% of type 2 diabetes mellitus (T2DM) patients who have had disease for more than 20 years [2].

Considering the large burden of this disease and also the limitations of available therapies, there is great interest in developing new strategies to prevent DR [3]. Studies have investigated the potential risk factors of DR and it has been shown that increasing age, disease duration, hyperglycemia and hypertension will increase the risk of development and progression of DR [4]. Moreover, it has been reported that inflammation has a role in the pathogenesis and development of DR [5]. On the other hand, it has been documented that there is link between inflammation and metabolic syndrome, diabetes and cardiovascular diseases (CVD). In this regard, diabetic patients are susceptible to CVD and mortality rate of CVD is high among these patients. Above mentioned risk factors are known as traditional risk factors of DR, however it has been shown that, even when glycemia and hypertension are under control, the number of diabetic patients with DR is increasing. Therefore, recent investigations have aimed for the identification of new and multiple risk factors of DR and some researchers have focused on diet and its role in the development and progression of DR. The role of diet in development of diabetes has been known but its role in DR has been much less evaluated [6]. Only one study evaluated the role of whole diet as Mediterranean diet in developing DR and others assessed food groups, macro, micronutrients and individual nutrient[7]. The findings of these studies are inconclusive [8]. The findings of these studies indicated that mediatranian diet, high fruit, vegetable, reduced caloric intake may reduce risk of DR.

Although different studies have been conducted on the association of DR and diet, to the best of our knowledge, there is no published article on the association between inflammatory potential of diet as measured by the dietary inflammatory index (DII®) and DR. However, the DII has been shown to be associated with T2DM and metabolic syndrome (MetS) in several studies [9, 10]. Therefore, the aims of present study were to study the association between DR, DII and MetS components in patients with T2DM in the Azar cohort study in Iran.

2. Methods

Data from this cross-sectional study were obtained from the Azar cohort study (including eye cohort study), in Shabestar in East Azerbaijan province (North West of Iran) which is part of the larger Persian cohort study (Prospective Epidemiological Research Studies of Iranian Adults) [11]. Azar cohort study was explained with more details in other published article [12]. This study was approved by Ethics Committee of Tabriz University of Medical Sciences (tbzmed.rec.1393.205). Written informed consent was obtained from all participants.
A total of 11,791 subjects participated in the Azar eye cohort study. Eye examinations were performed in all participants and a questionnaire regarding eye-specific medical history was completed and a visit by a trained optometrist to assess refractive error were done. Fundus photography and slit photos also were obtained for all participants. In addition, subjects who met certain screening criteria received a complete ophthalmological examination [11]. Based on the aim of the present study, subjects who had T2DM (n = 2012; 13.4%) were selected. Participants who did not have a fundus photograph (n = 625), who had a history of gestational diabetes mellitus (n = 6) or type 1 diabetes (n = 3) were excluded. Statistical analysis was performed on the remaining 1378 patients with type 2 diabetes.

2.1. Demographic characteristics of participants

The demographic characteristics of the participants; i.e., age, gender, marital status and educational level, were collected by questionnaire. Individual habits such as smoking, drug use, hookah, and alcohol consumption and being passive smokers were evaluated by questionnaire. Socio-economic status was defined based on job category, educational level and family assets using principal component analysis. Socioeconomic status was classified as very high, high, middle, low or very low based on a quintuple of obtained scores [13].

2.2. Anthropometric and blood pressure measurements

Weight, height and waist circumference were measured and the body mass index (BMI) was calculated by dividing the weight (kg) by the height (m) squared. The anthropometric measurements are described in detail elsewhere [11]. Blood pressure was measured twice on one day with an interval of two minutes and twice in each arm in a sitting position after 10 minutes of rest by a trained nurse using a mercury sphygmomanometer (Rudolf Richter; DE-72417; Germany). The averages of these two measurements were considered as the systolic and diastolic blood pressure.

2.3. Biochemical Factors

Blood samples were collected after an overnight fast of ≥ 12 hours. Fasting blood sugar (FBS), serum triglyceride (TG), high density lipoprotein (HDL) were determined by enzymatic methods. Low density lipoprotein (LDL) was calculated by Friedewald's formula.

2.4. Definition of diabetes and MetS

Participants were considered to have diabetes if they were currently using glucose-lowering medications or if they had FBS ≥ 126 mg/dl or Hb1AC ≥ 6.5% [14]. Type 1 diabetes was determined on the basis of medical history, age at onset of diabetes and treatment type for glycemic control. Any diabetic that did not have Type 1 diabetes was classified as having T2DM.

MetS was defined according to the National Cholesterol Education Program Adult Treatment Panel III report criteria (ATP III) [15]. Subjects with three or more of the following conditions were defined as having MetS: waist circumference ≥ 102 cm in men and ≥ 88 cm in women, TG ≥ 150 mg/dl (drug treatment for elevated triglycerides is an alternate indicator), HDL-C values of < 40 mg/dl in men and < 50 mg/dl in women. Hypertension was defined as elevated systolic blood pressure (≥ 130) and/or diastolic (≥ 85) mmHg or the use of antihypertensive medication. Elevated fasting glucose was considered to be ≥ 100 mg/dl or the use of glucose-lowering medication.

2.5. Dietary inflammatory index (DII®)

Dietary intake of subjects was evaluated by food frequency questionnaire which was completed by trained nutritionist. Each food item was converted to gr/day and then analyzed by Nutritionist IV. The energy-adjusted DII (E-DII) score was calculated on the basis of Shivappa et al. method which is described in detail elsewhere [16]. The food parameters included in calculation of the E-DII in this study were vitamin B12, vitamin B6, -carotene, caffeine, carbohydrate, cholesterol, energy, total fat, fiber, vitamin B9, iron, magnesium, mono-unsaturated fatty acid, vitamin B3, 3 fatty acids, -6 fatty acids, protein, poly unsaturated fatty acids, vitamin B2, saturated fatty acid, selenium, vitamin B1, vitamin A, vitamin C, vitamin D, vitamin E and zinc, tea, garlic and onion. All food items were adjusted for energy using the energy density method.

More negative DII scores are correlated with anti-inflammatory diet and more positive scores indicate more pro-inflammatory diet [16].
2.6. Diabetic retinopathy assessment

According to Azar cohort protocol, after maximal dilation of the pupils using mydrax 1% to each eye, two photographs were captured by a digital fundus camera (TRC-NW6S; Topcon; Japan) equipped with a Nikon D-80 digital camera (Nikon; Japan). All patients underwent 45°, two-field macula-centered fundus imaging. For determining risk factors of DR, DR severity was classified as non-proliferative diabetic retinopathy (NPDR) or proliferative diabetic retinopathy (PDR). If DR was diagnosed in both eyes and the severity was different in each eye, the highest stage of DR was considered for statistical analysis.

2.7. Statistical Analysis

Data was presented using mean (SD) and frequency (percentage) for the numeric and categorical variables, respectively. To investigate the association between the levels of DR and systemic factors, univariable and multivariable logistic regression modeling were used. In multivariable analysis, the models were adjusted for age, gender, marital status, and socioeconomic status, place of residence, cigarette smoking, hookah smoking, and drug use and alcohol consumption. In the analysis, the odds ratios (ORs) and 95% confidence interval (CI) were presented. To compute the p-value for trend, categorical variables were entered into logistic model quantitatively. All analyses were conducted in SPSS® 17 (SPSS; USA) and statistical significance was set at p < 0.05.

3. Results

Of 1378 diabetic patients, 185 (13.4%) had NPDR and 142 (10.3%) had PDR. The characteristics of the patients stratified by level of DR are presented in Table 1. A rate of patients with obesity, MetS, abdominal obesity, hypo-HDL cholesterolemia and hypertriglyceridemia was higher in diabetic patients without DR than in those with NPDR and PDR. Moreover, the percentage of patients with uncontrolled blood glucose and blood pressure was higher in the PDR group than in the other study groups. According to E-DII quartile, 25.2%, 23.5%, and 24.8% of patients without DR, with NPDR, and PDR were in the most pro-inflammatory E-DII quartile (4th ).
Table 1
Baseline characteristics according to level of diabetic retinopathy (DR) in patients with type 2 diabetes from the Azar cohort study.

| Variables                  | No DR (n=1051) | Non proliferative DR (n=185) | Proliferative DR (n=142) |
|----------------------------|----------------|------------------------------|--------------------------|
| Age (years)                | N              | %                            | N                         | N                         | %                        |
| < 50                       | 302            | 28.7                         | 44                        | 23.8                      | 16                       | 11.3                     |
| ≥ 50                       | 749            | 71.3                         | 141                       | 76.2                      | 126                      | 88.7                     |
| Gender                     | N              | %                            | N                         | %                         | N                         | %                        |
| Male                       | 429            | 40.8                         | 86                        | 46.2                      | 73                        | 51                       |
| Female                     | 622            | 59.1                         | 99                        | 53.5                      | 69                        | 48.5                     |
| Marital status             | N              | %                            | N                         | %                         | N                         | %                        |
| Single                     | 86             | 8.2                          | 18                        | 9.7                       | 14                        | 9.8                      |
| Married                    | 965            | 91.8                         | 167                       | 90.3                      | 128                       | 90.2                     |
| Place of living            | N              | %                            | N                         | %                         | N                         | %                        |
| Urban                      | 793            | 75.5                         | 148                       | 80.0                      | 105                       | 73.9                     |
| Rural                      | 258            | 24.5                         | 37                        | 20.0                      | 37                        | 26.10                    |
| Socioeconomic status       | N              | %                            | N                         | %                         | N                         | %                        |
| Very low                   | 225            | 21.7                         | 43                        | 23.4                      | 39                        | 27.9                     |
| Low                        | 235            | 22.6                         | 38                        | 20.7                      | 28                        | 20.0                     |
| Middle                     | 226            | 21.8                         | 46                        | 25.0                      | 26                        | 18.6                     |
| High                       | 190            | 18.3                         | 35                        | 19.0                      | 25                        | 17.9                     |
| Very high                  | 162            | 15.6                         | 22                        | 12.0                      | 22                        | 15.7                     |
| BMI (kg/m²)                | N              | %                            | N                         | %                         | N                         | %                        |
| Normal (18.5–24.9)         | 119            | 11.3                         | 21                        | 11.4                      | 29                        | 20.4                     |
| Overweight (25–29.9)       | 396            | 37.7                         | 81                        | 43.8                      | 53                        | 37.3                     |
| Obese (≥ 30)               | 536            | 51                            | 83                        | 44.9                      | 60                        | 42.3                     |
| Metabolic syndrome         | N              | %                            | N                         | %                         | N                         | %                        |
| Yes                        | 822            | 78.3                         | 141                       | 76.2                      | 104                       | 74.8                     |
| No                         | 228            | 21.7                         | 44                        | 23.8                      | 35                        | 25.2                     |
| Metabolic syndrome components | N    | %                            | N                         | %                         | N                         | %                        |
| Abdominal obesity*         | 736            | 70.0                         | 118                       | 63.8                      | 89                        | 62.7                     |

* abdominal obesity: waist circumference in men ≥ 102 cm, in women ≥ 88 cm; § Hypo HDL-cholesterolemia: HDL-C < 40 mg/dl in men and < 50 mg/dl in women; # Glycemic control: Fasting blood sugar (FBS) = 80–130 mg/dL; ## hypertension: blood pressure < 140/90
The findings of multivariable logistic regression indicated that age > 50 years old (OR 3.21; 95% CI 1.87–5.49) and of female gender (OR 1.51; 95% CI 1.06–2.14) were significantly associated with PDR (Table 2). The results of the present study indicated that the risk of NPDR and PDR increased 2.65-fold and 2.01-fold, respectively, in patients with high blood glucose levels outside the recommended range (Tables 2). As shown in Table 3, there was no significant relationship between MetS in NPDR and PDR as compared to no DR. Among MetS components, only hypertension increased risk of PDR by 1.49(1.03–2.14). In this regard, we observed that patients within the normal range of BMI were more likely to have PDR (OR 2.14; 95% CI 1.32–3.48) (Table 3). As shown in Table 4, we did not find any significant association between different quartiles of DII and NPDR and PDR.

| Level of DR     | No DR (n* = 1051) | Non proliferative DR (n* = 185) | Proliferative DR (n* = 142) |
|-----------------|------------------|---------------------------------|----------------------------|
| Hypertension    | 557              | 109                             | 87                         |
| Hypo HDL-cholesterolemia§ | 666 | 112                             | 81                         |
| Hypertriglyceremia§§ | 557 | 91                             | 70                         |
| Glycemic control # |                  |                                 |                            |
| Not controlled  | 448              | 131                             | 93                         |
| Newly diagnosed diabetes | 156 | 5                              | 4                          |
| Controlled      | 447              | 49                             | 45                         |
| Hypertension ** |                  |                                 |                            |
| Not controlled  | 167              | 29                             | 34                         |
| Controlled      | 880              | 155                            | 105                        |
| Cholesterol     |                  |                                 |                            |
| ≥ 200 mg/dl     | 427              | 63                             | 53                         |
| < 200 mg/dl     | 624              | 122                            | 89                         |
| LDL-cholesterol |                  |                                 |                            |
| ≥ 100(mg/dl)    | 648              | 102                            | 78                         |
| < 100(mg/dl)    | 398              | 80                             | 64                         |

* abdominal obesity: waist circumference in men ≥ 102 cm, in women ≥ 88 cm; § Hypo HDL-cholesterolemia: HDL-C < 40 mg/dl in men and < 50 mg/dl in women; # Glycemic control: Fasting blood sugar (FBS) = 80–130 mg/dL; ** hypertension: blood pressure < 140/90
Table 2
The association of demographic and baseline characteristics of study subjects with non-proliferative and proliferative diabetic retinopathy

| variables            | Non proliferative DR (n = 185) | P     | Proliferative DR (n = 142) | P     |
|----------------------|--------------------------------|-------|---------------------------|-------|
|                      | OR (95%CI)                     |       | OR (95%CI)                |       |
| **Age (Year)**       |                                |       |                           |       |
| < 50                 | Reference                      |       |                           |       |
| ≥ 50                 | 1.26(0.88–1.81)                 | 0.19  | 3.21(1.87–5.49)           | < 0.001 |
| **Gender**           |                                |       |                           |       |
| Male                 | 1.24(0.91–1.70)                 | 0.16  | 1.51(1.06–2.14)           | 0.02  |
| Female               | Reference                      |       |                           |       |
| **Socioeconomic status** |                                |       |                           |       |
| Very low             | 1.40(0.81–2.44)                 | 0.22  | 1.22(0.70–2.12)           | 0.48  |
| Low                  | 1.19(0.67–2.08)                 | 0.54  | 0.87(0.48–1.58)           | 0.66  |
| Middle               | 1.49(0.86–2.57)                 | 0.15  | 0.84(0.46–1.54)           | 0.58  |
| High                 | 1.39(0.78–2.46)                 | 0.25  | 0.96(0.52–1.78)           | 0.91  |
| Very High            | Reference                      |       |                           |       |
| **Glycemic control** |                                |       |                           |       |
| Not controlled       | 2.08(1.42–3.03)                 | < 0.001 | 2.01(1.36–2.97)           | < 0.001 |
| Newly diagnosed      | 0.25(0.09–0.72)                 | < 0.001 | 0.25(0.08–0.72)           | < 0.001 |
| Controlled           | Reference                      |       |                           |       |

# Glycemic control: if Fasting blood sugar (FBS) = 80–130 mg/dL, it was considered as glycemic control
| Variables                                      | Non proliferative DR       | P       | adjusted OR (95%CI)     | P       | Unadjusted OR (95%CI)     | P       | adjusted OR (95%CI)     | P       |
|------------------------------------------------|-----------------------------|---------|-------------------------|---------|---------------------------|---------|-------------------------|---------|
| **BMI (kg/m²)**                                |                             |         |                         |         |                           |         |                         |         |
| Normal (18.5–24.9)                             | 1.12 (0.67–1.89)            | 0.64    | 1.02 (0.6–1.76)         | 0.91    | 2.14 (1.32–3.48)          | 0.002   | 1.12 (0.67–1.89)         | 0.64    |
| Over weight (25–29.9)                          | 1.30 (0.93–1.82)            | 0.11    | 1.21 (0.8–1.70)         | 0.26    | 1.17 (0.79–1.74)          | 0.41    | 1.30 (0.93–1.82)         | 0.11    |
| Obese (≥ 30)                                   | Reference                   |         |                         |         |                           |         |                         |         |
| Metabolic syndrome                             | 0.88 (0.61–1.28)            | 0.53    | 0.88 (0.60–1.28)        | 0.52    | 0.82 (0.54–1.24)          | 0.35    | 0.78 (0.51–1.18)         | 0.24    |
| Metabolic syndrome components                  |                             |         |                         |         |                           |         |                         |         |
| Abdominal obesity**                            | 1.37 (0.95–1.82)            | 0.09    | 1.19 (0.82–1.72)        | 0.35    | 1.37 (0.95–1.98)          | 0.08    | 1.18 (0.771.79)          | 0.35    |
| Hypertension                                   | 1.29 (0.94–1.77)            | 0.11    | 1.32 (0.94–1.84)        | 0.10    | 1.49 (1.03–2.14)          | 0.03    | 1.34 (0.91–1.97)         | 0.13    |
| Hypertriglyceremia†                            | 0.85 (0.62–1.16)            | 0.31    | 0.88 (0.64–1.21)        | 0.43    | 0.85 (0.6–1.20)           | 0.37    | 0.95 (0.66–1.36)         | 0.78    |
| Hypo-HDL-cholesterolemia§                       | 0.87 (0.63–1.20)            | 0.40    | 0.92 (0.66–1.27)        | 0.61    | 0.77 (0.54–1.10)          | 0.16    | 0.83 (0.58–1.20)         | 0.34    |
| Total cholesterol ≥ 200 mg/dl                  | 0.74 (0.53–1.03)            | 0.08    | 0.77 (0.55–1.08)        | 0.13    | 0.85 (0.59–1.23)          | 0.40    | 0.93 (0.64–1.36)         | 0.73    |
| Total cholesterol < 200 mg/dl                  | Reference                   |         |                         |         |                           |         |                         |         |
| LDL-cholesterol ≥ 100 mg/dl                    | 0.77 (0.56–1.01)            | 0.11    | 0.79 (0.57–1.09)        | 0.16    | 0.73 (0.51–1.04)          | 0.08    | 0.75 (0.52–1.07)         | 0.12    |
| LDL-cholesterol < 100 mg/dl                    | Reference                   |         |                         |         |                           |         |                         |         |

*n = number; ** abdominal obesity: waist circumference in men ≥ 102 cm, in women ≥ 88 cm; † Hypo HDL-cholesterolemia: HDL-C < 40 mg/dl in men and < 50 mg/dl in women; ‡ Hypertriglyceridemia: triglyceride ≥ 150 mg/dl; § adjusted for age, gender, marital status, socioeconomic status, place of living, cigarette smoking, hookah smoking use of drugs, drinking alcohol
### Table 4

| Non proliferative DR | P | Adjusted OR (95%CI) | P | Unadjusted OR (95%CI) | P | Adjusted OR (95%CI) | P |
|----------------------|---|--------------------|---|----------------------|---|--------------------|---|
| Dietary inflammatory index | | | | | | | |
| Q1: -3.57-1.084 | Unadjusted | 0.82 | 0.83(0.53–1.30) | 0.43 | 1.00 (0.60–1.66) | 0.98 | 1.05(0.63–1.77) | 0.83 |
| | Adjusted | 0.82 | 0.83(0.53–1.30) | 0.43 | 1.00 (0.60–1.66) | 0.98 | 1.05(0.63–1.77) | 0.83 |
| Q2: -2.10-1.51 | Unadjusted | 0.84 | 0.84(0.53–1.3) | 0.44 | 1.03(0.63–1.71) | 0.88 | 1.03(0.61–1.73) | 0.91 |
| | Adjusted | 0.84 | 0.84(0.53–1.3) | 0.44 | 1.03(0.63–1.71) | 0.88 | 1.03(0.61–1.73) | 0.91 |
| Q3: -1.60-2.39 | Unadjusted | 0.86 | 0.86(0.55–1.34) | 0.52 | 1.04(0.63–1.71) | 0.87 | 1.13(0.68–1.89) | 0.62 |
| | Adjusted | 0.86 | 0.86(0.55–1.34) | 0.52 | 1.04(0.63–1.71) | 0.87 | 1.13(0.68–1.89) | 0.62 |
| Q4: -1.31-5.45 | Reference | | | | | | Reference |

*Adjusted for age, gender, marital status, socioeconomic status, place of living, cigarette smoking, hookah smoking use of drugs, drinking alcohol*

### 4. Discussion

The results of this study indicated that the duration of diabetes, high blood glucose, and high blood pressure were associated with DR and, in particular, PDR. In this study of 1378 diabetic patients, 185 (13.4%) had NPDR and 142 (10.3%) had PDR. The prevalence of DR varies by country from 9.6% in India to 43.1% in Indonesia. The prevalence of DR in different provinces of Iran have been reported to be 30.5% in Tehran to 76.4% in Isfahan [17]. It should be noted that, in most studies, a prevalence of DR of 30%-40% has been reported [17]. The wide range of prevalence in various regions can be ascribed to the type and duration of diabetes, ethnicity [18], method of DR determination (fundus photograph or ophthalmoscopy) and level of awareness and self-management of diabetes [19]. In the terms of systemic factors, the current results are similar to those of previous studies which reported the duration of diabetes, poor glycemic control and high blood pressure as important determinants of the risk of incidence and progression of DR [20–22].

No significant relationship was found between DR and MetS. In line with these findings, Chen et al. [23] reported that the prevalence of MetS was high in diabetic patients, but there was no significant association with the incidence and severity of DR. The results of the Korean National Health and Nutrition Examination Surveys also showed that MetS and its components did not increase the risk of DR [24]. On the other hand, some studies have reported a positive relationship between MetS and DR [25–27]. In this regard, Bonadonna et al. [25] noted that the risk of DR increased 1.49-fold in diabetic patients as compared with patients without MetS. The discrepancy between the results of different studies may be due to the use of different criteria for defining MetS and DR.

In the current study, diabetic patients with normal BMI values had 83% higher odds of DR compared with obese patients. This association has been supported by previous studies in Asia which have reported no significant or inverse relationship between BMI and DR [28–31]. The results of Asian and Western studies differ in this respect. In Australian diabetic patients, a higher BMI increased the risk of DR [32], which is the opposite of the results of the aforementioned Asian studies [28, 30, 31]. We have no explanation for the relationship between normal BMI and DR; it was assumed that BMI might not be as good indicator of obesity as percentage of body fat.

The results of regression analysis indicated that there was no significant association between a high level of TG, total cholesterol, LDL-C and lower level of HDL-C and DR. These results are in agreement with the results of earlier large population-based studies [33, 34]. In contrast, in other studies, dyslipidemia in diabetic patients has been reported to be a risk factor for DR [35, 36]. The contradictory results can be attributed to differences in ethnicity, race, genetics, geographical area and life style.
In this study, we could not confirm an association between the DII and DR. It has been reported that inflammation plays an important role in the development of DR. In this regard, findings of previous studies indicated that using anti-inflammatory agent such as salicylates or minocycline had positive effects in preventing the progression of DR.[37, 38]. According to these results, recently researchers noted the DII may influence the development of DR. As far as we know this is the first study which examines the association between DII and DR. Previous studies evaluated the role of whole diet or individual nutrient in incidence and development of DR. The result of systematic review study by Wong et al indicated that dietary fibre, oily fish, a Mediterranean diet and a reduced caloric intake can reduce the risk of DR.[8]. The role of antioxidants, fatty acids, proteins and alcohol are not well described.[8]. Because there is no study about DII and DR we have to compare our results with studies that evaluate dietary factors that have anti-inflammatory role such as vitamin C, carotenoids, vitamin E, etc.

Tanka et al noted vitamin C decreased risk of DR[39], while findings of other cross-sectional studies did not report this inverse association.[40, 41]. Dow et al reported that results of various studies showed there was no association between vitamin E, carotenoids, and vitamin D [42]. The findings of the present study are similar to these other studies. It is conceivable that no significant association between DII and DR may be due to recall bias involved in completing the FFQ. Most patients in our study had diabetes when they participated in the cohort study. Thus, they may have changed their diets on the basis of physician advice factors. Also, they may have been embarrassed to report a bad (i.e., pro-inflammatory diet). For example we know that dietary self-reports are often biased by response sets such as social desirability and social approval.[43, 44]. These could be explanations for the absence of an observed association between DII and DR.

The present study had some limitations, including its cross-sectional design and the fact that HbA1C could not be measured in all study participants. As noted, there are potential information biases that result from self-report of dietary intake. Despite its weaknesses, the present study has several strengths. DR was identified on the basis of fundus photography with pupil dilation, which is the best method of determining DR.[45]. Moreover, the very large sample of diabetic patients improves statistical power. Other strength of present study is the assessment of dietary inflammatory index as a possible risk factor for the development of DR. however, this also may be limited by the self-reported nature of the dietary data.

In conclusion, the results showed that poor glycemic control, and high blood pressure was associated with advanced levels of DR. Therefore, in confirmation of previous studies, intensive glycemic control rather than conventional control can be helpful in the prevention of the incidence and progression of DR.[46, 47]. Moreover, there is a need to increase self-care awareness of diabetic patients about achieving the goal of glycemic and blood pressure control. We could not confirm the association between DII and DR. It seems that longitudinal studies and clinical trials for evaluating role of dietary-associated inflammation in DR are necessary.

Abbreviation List

Diabetic retinopathy: DR
Dietary inflammatory index : DII
Metabolic syndrome : MetS
Non-proliferative diabetic retinopathy: NPDR
Proliferative diabetic retinopathy: PDR
Type 2 Diabetes Mellitus : T2DM
Cardiovascular Diseases : CVD
Fasting blood sugar : FBS
Triglyceride : TG
High density lipoprotein : HDL
Low density lipoprotein: LDL

Body mass index: BMI

energy-adjusted DII : E-DII

Declarations

Ethics approval and consent to participate

This study was approved by the ethic committee of Tabriz University of medical sciences (tbzmed.rec.1393.205).

Consent for publication

Not Applicable

Availability of data and materials

The data that support the findings of this study are available from [Vice Chancellor for Research] but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of [Vice Chancellor for Research]

Competing interests

The authors declare that they have no competing interests

Funding

This study was supported by the liver and gastrointestinal diseases research center, Tabriz University of Medical Sciences. The funder had no role on the study design, data analysis, interpreting and writing the manuscript in this study. Grant number700/108 on 14 March 2016.

Authors' contributions

-The conception or design of the work: MHS,AR0,ZN,EF

-The acquisition, analysis:ZN,EF,NS,JRH

OR interpretation of data:EF,ZN,MAJ

Drafted the work or substantively revised:EF,NF,SZ,UH,JG,MM

All authors have read and approved the manuscript

Acknowledgments:

The authors are grateful for the financial support of the liver and gastrointestinal diseases research center, Tabriz University of Medical Sciences. The authors also are deeply indebted to all subjects who participated in this study. We thank the close collaboration of the Shabestar health center. In addition, we would like to thank the Persian cohort study staff for their technical support.

Disclosure: Dr. James R. Hébert owns controlling interest in Connecting Health Innovations LLC (CHI), a company that has licensed the right to his invention of the dietary inflammatory index (DII®) from the University of South Carolina in order to develop computer and smart phone applications for patient counseling and dietary intervention in clinical settings. Dr. Nitin Shivappa is an employee of CHI. The subject matter of this paper will not have any direct bearing on that work, nor has that activity exerted any influence on this project.
References

1. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet 2010; 376(9735):124-136.
2. American Diabetes Association. Diabetic Retinopathy. Diabetes Care. 2002; 25(suppl 1):s90-s93.
3. Gholamhossein Y, Behrouz H, Asghar Z. Diabetic retinopathy risk factors: plasma erythropoietin as a risk factor for proliferative diabetic retinopathy. Korean J Ophthalmol. 2014; 28(5):373-378.
4. Moreno A, Lozano M, Salinas P. Diabetic retinopathy. Nutricion Hospitalaria. 2013;28 Suppl 2:53-56.
5. Noda K, Nakao S, Ishida S, Ishibashi T. Leukocyte adhesion molecules in diabetic retinopathy. J ophthalmol. 2011;2012.
6. Alhazmi A, Stojanovski E, McEvoy M, Garg M. The association between dietary patterns and type 2 diabetes: a systematic review and meta-analysis of cohort studies. J Human Nut Diet. 2014; 27(3):251-260.
7. Dow C, Mancini F, Rajaobelina K, Boulton-Ruault M-C, Balkau B, Bonnet F, et al. Diet and risk of diabetic retinopathy: A systematic review. Eur J Epidemiol. 2018; 33(2):141-156.
8. Wong MY, Man RE, Fenwick EK, Gupta P, Li L-J, van Dam RM, et al. Dietary intake and diabetic retinopathy: A systematic review. Plos One. 2018; 13:e0186582.
9. Mtintsilana A, Micklesfield LK, Chorell E, Olsson T, Shivappa N, Hebert JR, et al. Adiposity Mediates the Association between the Dietary Inflammatory Index and Markers of Type 2 Diabetes Risk in Middle-Aged Black South African Women. Nutrient. 2019;11(6):1246.
10. Denova-Gutierrez E, Munoz-Aguirre P, Shivappa N, Hebert JR, Tolentino-Mayo L, Batis C, Dietary Inflammatory Index and Type 2 Diabetes Mellitus in Adults: The Diabetes Mellitus Survey of Mexico City. Nutrients. 2018; 10(4).
11. Poustchi H, Eghtesad S, Kamangar F, Etemadi A, Keshk A-A, Hekmatdoost A, Mobinmadi Z, Mahmoudi Z, Shayanrad A, Rozaafzi F: Prospective Epidemiological Research Studies in Iran (The PERSIAN Cohort): Rationale, Objectives and Design. Am J Epidemiol. 2018;187:647-655.
12. Farhang S, Faramarzi E, Amini Sani N, Poustchi H, Ostadrahimi A, Alizadeh BZ, Somi MH: Cohort profile: The AZAR cohort, a health-oriented research model in areas of major environmental change in Central Asia. Inter J Epidemiol. 2019; 48:382-382h.
13. Jolliffe IT: Principal component analysis. New York: Springer; 1986.
14. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2014; 37(Supplement 1):S81-S90.
15. Grundy SM, Brewer Jr HB, Cleeman JI, Smith Jr SC, Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109(3):433-438.
16. Shivappa N, Steck SE, Hurley TG, Hussey JR, Hebert JR. Designing and developing a literature-derived, population-based dietary inflammatory index. Public Health Nutr. 2014; 17(8):1689-1696.
17. Javadi MA, Katibeh M, Rafati N, Dehghan MH, Zayeri F, Yaseri M, et al. Prevalence of diabetic retinopathy in Tehran province: a population-based study. BMC Ophthalmol. 2009; 9(1):12.
18. Kou S, Cao JY, Yeo S, Holmes-Walker DJ, Lau SL, Gunton JE. Ethnicity influences cardiovascular outcomes and complications in patients with type 2 diabetes. J Diabe Complications. 2018; 32(2):144-149.
19. Chua J, Lim CXY, Wong TY, Sabanayagam C: Diabetic Retinopathy in the Asia-Pacific. Asia-Pacific J Ophthalmol (Philadelphia, Pa). 2018; 7(1):3-16.
20. Reddy D, Rani PK, Jalali S, Rao HL. A Study of Prevalence and Risk Factors of Diabetic Retinopathy in Patients with Non-Arteritic Anterior Ischemic Optic Neuropathy (NA-AION). Seminar Ophthalmol. 2015;30(2):101-104.
21. Sasongko MB, Widyaputri F, Agni AN, Wardhana FS, Kotha S, Gupta P, Widayanti TW, Haryanto S, Widyaningrum R, Wong TY et al: Prevalence of Diabetic Retinopathy and Blindness in Indonesian Adults With Type 2 Diabetes. Am J Ophthalmol. 2017; 181:79-87.
22. Tan GS, Gan A, Sabanayagam C, Tham YC, Neelam K, Mitchell P, Wang JJ, Lamoureux EL, Cheng C-Y, Wong TY: Ethnic Differences in the Prevalence and Risk Factors of Diabetic Retinopathy: The Singapore Epidemiology of Eye Diseases Study. Ophthalmol. 2018;125(4):529-536.
23. Chen JJ, Wendel LJ, Birkholz ES, Vallone JG, Coleman AL, Yu F, Mahajan VB. The metabolic syndrome and severity of diabetic retinopathy. Clin Ophthalmol. 2015; 9: 757.

24. Kim TK, Won JY, Shin JA, Park Y-M, Yim HW, Park Y-H. The Association of Metabolic Syndrome with Diabetic Retinopathy: The Korean National Health and Nutrition Examination Survey 2008–2012. PLoS ONE. 2016;11(6):e0157006.

25. Bonadonna R, Cucinotta D, Fedele D, Riccardi G, Tiengo A. The metabolic syndrome is a risk indicator of microvascular and macrovascular complications in diabetes: results from Metascreen, a multicenter diabetes clinic-based survey. Diabetes Care. 2006; 29(12):2701-2707.

26. Gao L, Xin Z, Yuan M-X, Cao X, Feng J-P, Shi J, et al. High Prevalence of Diabetic Retinopathy in Diabetic Patients Concomitant with Metabolic Syndrome. PLoS ONE. 2016; 11(1): e0145293.

27. Costa LA, Canani LH, Lisboa HR, Tres GS, Gross JL. Aggregation of features of the metabolic syndrome is associated with increased prevalence of chronic complications in Type 2 diabetes. Diabetic Med. 2004;21(3):252-255.

28. Bonadonna R, Cucinotta D, Fedele D, Riccardi G, Tiengo A. The metabolic syndrome is a risk indicator of microvascular and macrovascular complications in diabetes: results from Metascreen, a multicenter diabetes clinic-based survey. Diabetes Care. 2006; 29(12):2701-2707.

29. Pang C, Jia L, Jiang S, Liu W, Hou X, Zuo Y, Gu H, Bao Y, Wu Q, Xiang K: Determination of diabetic retinopathy prevalence and associated risk factors in Chinese diabetic and pre-diabetic subjects: Shanghai diabetic complications study. Diabmetabolism Res Rev. 2012;28(3):276-283.

30. Man REK, Sabanayagam C, Chiang PP-C, Li L-J, Noonan JE, Wang JJ, Wong TY, Cheung GC-M, Tan GSW, Lamoureux EL: Differential association of generalized and abdominal obesity with diabetic retinopathy in Asian patients with type 2 diabetes. JAMA Ophthalmol. 2016; 134(3):251-257.

31. Rooney D, Lye WK, Tan G, Lamoureux EL, Ikram MK, Cheng C-Y, Kumari N, Zheng YF, Mitchell P, Wang JJ: Body mass index and retinopathy in Asian populations with diabetes mellitus. Acta Diabetologica. 2015; 52(1):73-80.

32. Dirani M, Xie J, Fenwick E, Benarous R, Rees G, Wong TY, et al. Are obesity and anthropometry risk factors for diabetic retinopathy?: the diabetes management project. Invest Ophthalmol Visual Sci. 2011; 52(7):4416-4421.

33. Wong TY, Cheung N, Tay WT, Wang JJ, Aung T, Saw SM, et al. Prevalence and risk factors for diabetic retinopathy: the Singapore Malay Eye Study. Ophthalmol. 2008;115(11):1869-1875.

34. Dow C, Mancini F, Rajaobelina K, Boutron-Ruault M-C, Balkau B, Fagherazzi G, et al. Diet and risk of diabetic retinopathy: A systematic review. Eur J Epidemiol. 2018;33(2):141-56.

35. Hebert JR, Hurley TG, Peterson KE, Resnicow K, Thompson FE, Yaroch AL, Ehlers M, Midthune D, Williams GC, Greene GWJT: Jon. Social desirability trait influences on self-reported dietary measures among diverse participants in a multicenter multiple risk factor trial. J Nutr. 2008;138(1):226S-34S.
44. Hébert JRJJotAaN, Dietetics: Social desirability trait: biaser or driver of self-reported dietary intake? J Academy Nutr Diet. 2016;116(12):1895-8.

45. Hutchinson A, McIntosh A, Peters J, O’Keeffe C, Khunti K, Baker R, Booth A: Effectiveness of screening and monitoring tests for diabetic retinopathy—a systematic review. Diabetic Med. 2000; 17(7):495-506.

46. Control D, Group CTR: The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabete. 1995; 44(8):968-983.

47. Group UPDS: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352(9131):837-853.